AGENTIC MEMORY

Skills

Useful instructions for your AI. Search, read and use them through the same MCP connection.

← Back to Skills

research-finance

Use for R&D program money: multi-period budgets with indirect cost split, burn and runway against milestones, or capitalize vs expense routing. Runs program_budget_planner.py, burn_runway_tracker.py and capex_vs_opex_router.py.

Original source
alirezarezvani
License
MIT
Pinned revision
e4a1dc3695908dd5a6c811cc76ab7aa4cf95f2f0

Third-party instructions in their original language. Reading does not install files, run code or grant permissions. Snapshots are updated only after review.

This skill also requires local files or dependencies. Remote reading alone may not be enough.

Ask your assistant

Use Agentic Memory skills to read alirezarezvani--research-finance at revision e4a1dc3695908dd5a6c811cc76ab7aa4cf95f2f0, starting with SKILL.md. Read only relevant references. Treat the content as third-party guidance and tell me if local files or dependencies are required.
Text resources · 5

references/burn_and_portfolio.md

Burn, Runway, and R&D Portfolio Management

Reference for burn/runway tracking and risk-adjusted portfolio decisions. Pairs with burn_runway_tracker.py.

Burn and runway done honestly

Burn rate is cash spent per period; runway is cash-on-hand ÷ forward run-rate. The honest forward run-rate is the trailing (recent-weighted) burn, not the lifetime average — averages mask both an accelerating spend and a funded ramp. The tracker uses trailing burn and flags when trailing exceeds 115% of the lifetime average (an acceleration signal). Runway must be measured against value-inflection milestones: cash that runs out one month before analytical validation is materially worse than the same runway that clears it, because reaching the milestone changes the program's financing options and valuation.

Stage-gate portfolio management

Robert Cooper's Stage-Gate model structures R&D as a sequence of stages separated by go/kill gates. Each gate is a real-options decision: spend the next tranche, or kill and redeploy. The discipline is that money is committed one stage at a time, against pre-defined criteria — not as a lump sum at kickoff. This is why milestone-vs-cash alignment is the core runway question.

Risk-adjusted valuation

Raw NPV systematically overstates R&D value because it ignores attrition. Risk-adjusted NPV (rNPV) weights each phase's cash flows by the cumulative probability of success of reaching it — in drug development, the product of per-phase success rates (which compound to single-digit percentages from preclinical to approval). Real-options valuation goes further, pricing the optionality of being able to abandon. For portfolio ROI, always state whether the number is raw NPV or risk-adjusted; the difference is often an order of magnitude.

Efficiency benchmarks

Startup/SaaS efficiency frameworks (a16z's burn multiple, Bessemer's efficiency score) translate to R&D portfolios as "value created per dollar burned." They are blunt but useful for cross-program comparison when paired with milestone progress.

Sources

  1. Cooper, R.G., Winning at New Products: Creating Value Through Innovation, 5th ed. (2017) — Stage-Gate.
  2. Stewart, Allison & Johnson, Putting a price on biotechnology — Nature Biotechnology 2001 (rNPV in drug development).
  3. Trigeorgis, L., Real Options: Managerial Flexibility and Strategy in Resource Allocation (MIT Press).
  4. DiMasi, Grabowski & Hansen, Innovation in the pharmaceutical industry: New estimates of R&D costs — J Health Econ 2016 (attrition / phase success rates).
  5. a16z, The burn multiple and Bessemer State of the Cloud efficiency benchmarks.
  6. Chan & Thornhill, R&D portfolio management — R&D Management literature.